Pharmacy Drugs
Recent Posts
- Democrats Push Medical Device Liability Bill
- FDA Investigates Heparin Link in Two Delaware Deaths
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Random Posts
- FDA Clarifies Access to Investigational Drugs
- Allos Therapeutics Completes Enrollment In Randomized Phase 2b Trial Of Pralatrexate In Patients With Advanced Non-Small Cell Lung Cancer
- Founder Of The Royal Pharmaceutical Society Commemorated In Tunbridge Wells
- ExonHit Announces Last Patient Out For EHT 0202 Phase IIa Study In Alzheimer's
- Rise In New Cases Of Alzheimer's And Dementia, Even In The 'Oldest Old'
- 2008 Workforce Census Published - Royal Pharmaceutical Society Of Great Britain
- Hospital Trust Recruiting For Trials Of New Flu Vaccine, UK
- Industry Asked To Fund Government Purchasing, Australia
- DOR BioPharma Receives EMEA Agreement On The Design Of Its Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD
- Generic Propofol Contamination Prompts Limited Recall
Noven Reports Positive Phase 2 Results For Mesafem™ Non-Hormonal Therapy For Vasomotor Symptoms
Posted by: admin in Pharmacy Drugs on July 23rd, 2009
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced positive top-line results from its Phase 2 clinical study evaluating Mesafem™ (low-dose paroxetine mesylate) for the treatment of vasomotor symptoms (hot flashes) associated with menopause (”VMS”).
This was a multi-center, double-blind, randomized, placebo-controlled Phase 2 efficacy and safety study of Mesafem in the treatment of VMS. The eight-week study, sponsored by Noven, enrolled 102 patients (with 98 patients completing) at ten clinical locations in the U.S. Patients in the active arm of the study received a dose of Mesafem below 10mg once daily. The primary objective of the study was to assess the safety and efficacy of Mesafem for the treatment of VMS. The primary outcome measures were mean changes in frequency and severity of moderate-to-severe hot flashes from baseline to the fourth and eighth weeks of the study.
“Although designed and powered to detect an efficacy signal, we were very pleased to achieve statistical significance in several primary outcome measures, and to identify clear efficacy signals in the others,” said Joel S. Lippman, M.D., Noven’s Vice President - Clinical Development & Chief Medical Officer. “Safety and tolerability of Mesafem were similar to placebo, with no drug-related serious adverse events. In short, Mesafem appears to be efficacious and well-tolerated at the tested dose, and information from this study should permit us to develop and initiate a well-designed and cost-effective Phase 3 clinical program by year-end.”
Peter Brandt, Noven’s President & CEO, said: “Today’s Phase 2 results exceeded all our internal expectations from the standpoints of both efficacy and tolerability. With the data from this study, we plan to expedite Mesafem into Phase 3 development, and to advance our commercialization and partnering strategies, with the goal of making this new non-hormonal treatment option broadly available to women who suffer from VMS, but who are not candidates for, or who have concerns about, hormone therapy.”
Concurrent with this announcement, Noven issued a press release announcing that it had entered into a definitive merger agreement with Hisamitsu Pharmaceutical Co., Inc. That press release is available at http://www.noven.com.
Source
Noven Pharmaceuticals, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.